

Provided for non-commercial research and education use.
Not for reproduction, distribution or commercial use.



This article appeared in a journal published by Elsevier. The attached copy is furnished to the author for internal non-commercial research and education use, including for instruction at the authors institution and sharing with colleagues.

Other uses, including reproduction and distribution, or selling or licensing copies, or posting to personal, institutional or third party websites are prohibited.

In most cases authors are permitted to post their version of the article (e.g. in Word or Tex form) to their personal website or institutional repository. Authors requiring further information regarding Elsevier's archiving and manuscript policies are encouraged to visit:

<http://www.elsevier.com/copyright>



Contents lists available at ScienceDirect

Molecular & Biochemical Parasitology



Short communication

Plasmodium falciparum field isolates use complement receptor 1 (CR1) as a receptor for invasion of erythrocytes

Gordon A. Awandare^{a,b}, Carmenza Spadafora^c, J. Kathleen Moch^a, Sheetij Dutta^a,
J. David Haynes^a, José A. Stoute^{a,d,*}

^a Division of Malaria Vaccine Development, Walter Reed Army Institute of Research, Silver Spring, MD, United States

^b Department of Biochemistry, Cell and Molecular Biology, University of Ghana, Legon, Accra, Ghana

^c Instituto de Investigaciones Científicas y Servicios de Alta Tecnología-AIP (INDICASAT-AIP), Ciudad del Saber, Clayton, Panama

^d Department of Medicine, Division of Infectious Diseases, Pennsylvania State University College of Medicine, Hershey, PA, United States

ARTICLE INFO

Article history:

Received 15 October 2010

Received in revised form

23 December 2010

Accepted 5 January 2011

Available online 18 January 2011

Keywords:

Malaria

CR1

Red Cell

Invasion

Sialic acid

ABSTRACT

A majority of *Plasmodium falciparum* strains invade erythrocytes through interactions with sialic acid (SA) on glycoporphins. However, we recently reported that complement receptor 1 (CR1) is a SA-independent invasion receptor of many laboratory strains of *P. falciparum*. To determine the role of CR1 in erythrocyte invasion among *P. falciparum* field isolates, we tested eight isolates obtained from children in Kenya. All the parasites examined were capable of invading in a SA-independent manner, and invasion of neuraminidase-treated erythrocytes was nearly completely blocked by anti-CR1 and soluble CR1 (sCR1). In addition, anti-CR1 and sCR1 partially inhibited invasion of intact erythrocytes in a majority of isolates tested. Sequencing of the hypervariable region of *P. falciparum* AMA-1 showed considerable diversity among all the isolates. These data demonstrate that CR1 mediates SA-independent erythrocyte invasion in *P. falciparum* field isolates.

© 2011 Elsevier B.V. All rights reserved.

Plasmodium falciparum infections are the leading cause of malaria-related morbidity and mortality in sub-Saharan Africa [1]. An integral part of the parasite's life cycle in humans is the blood stage, during which parasites repeatedly invade and multiply in erythrocytes. This part of the life cycle is responsible for all the morbidity and mortality. Therefore, vaccines targeting this stage could potentially be effective in preventing disease. However, the development of a blood stage vaccine is hampered by a lack of adequate understanding of the molecular mechanisms through which the parasite invades erythrocytes. Furthermore, it is important that studies examining erythrocyte invasion pathways include field parasites since laboratory-adapted strains often differ significantly from clinical isolates.

It is known that sialic acid (SA) residues on glycoporphins are an important receptor for the invasion of erythrocytes by *P. falciparum* [2,3]. However, a significant number of laboratory-adapted and field strains of *P. falciparum* are capable of invading erythrocytes depleted of SA after treatment with neuraminidase [4–8],

indicating the existence of one or more SA-independent invasion pathways. In addition, studies of *P. falciparum* field isolates from Kenya demonstrated that the vast majority (~74%) of these parasites relied on an unknown trypsin-sensitive receptor for SA-independent invasion of erythrocytes [5,9].

Our recent investigations [10], now confirmed by others [11], have identified complement receptor 1 (CR1, CD35) as the major neuraminidase-resistant, trypsin-sensitive receptor used for SA-independent invasion of erythrocytes by laboratory strains of *P. falciparum*, including 3D7, 7G8, Dd2NM, and HB3. CR1 is a complement regulatory protein that serves as co-factor in the factor I-mediated cleavage of C3b to C3bi and also accelerates the decay of C3 and C5 convertases. Our previous studies and those of others have also shown that CR1 expression levels [12,13], as well as genetic polymorphisms that influence CR1 expression [14–16], are associated with susceptibility to severe malaria in children.

To extend our earlier findings with laboratory strains [10], we investigated the role of CR1 in mediating erythrocyte invasion by field isolates of *P. falciparum* by examining the ability of these isolates to invade erythrocytes in the presence of CR1 inhibitors in vitro. Parasite isolates used in this study were collected from children diagnosed with acute malaria at hospitals in western Kenya, under protocols approved by the Kenya National Ethical Committee and the Human Subjects Research Committee at the Walter

* Corresponding author at: Department of Medicine, Pennsylvania State University College of Medicine, 500 University Drive, Hershey, PA 17033, United States. Tel.: +1 717 531 8881; fax: +1 717 531 4633.

E-mail address: jstoute@psu.edu (J.A. Stoute).

Table 1
CR1-dependent invasion of erythrocytes by *P. falciparum* clinical isolates.

Parasites	Control	Anti-CR1	IgY	sCR1	α -2M/Fetuin
<i>Invasion of untreated erythrocytes expressed as % control (SD)</i>					
3D7 (n=3)	100.0	102.0 (3.5)	101.8 (5.2)	98.6 (4.7)	101.3 (3.6)
JASC8-19 (n=5)	100.0	82.6 (6.7)*	93.1 (4.6)	73.7 (7.1)*	100.2 (3.4)
SA005 (n=3)	100.0	90.2 (2.4)	93.5 (5.9)	69.4 (2.1)*	92.9 (3.8)
SA154 (n=3)	100.0	82.2 (7.0)	93.6 (1.9)	75.9 (8.3)	95.4 (3.4)
SA162 (n=4)	100.0	98.7 (3.8)	101.7 (3.6)	79.6 (2.9)*	99.5 (4.0)
SA222 (n=5)	100.0	84.7 (7.8)*	97.4 (4.5)	64.9 (3.9)*	100.9 (2.4)
SA250 (n=3)	100.0	82.8 (5.3)	92.9 (2.1)	72.9 (1.5)*	91.4 (1.4)
CM028 (n=5)	100.0	90.6 (8.9)*	99.9 (8.0)	70.5 (7.9)*	98.2 (5.3)
CM033 (n=3)	100.0	86.1 (4.9)*	99.0 (3.1)	78.9 (5.0)*	98.7 (5.4)
<i>Invasion of neuraminidase-treated erythrocytes expressed as % untreated control (SD)</i>					
3D7 (n=3)	62.1 (5.5)	15.8 (2.6)*	62.1 (4.7)	8.4 (2.3)*	60.6 (4.8)
JASC8-19 (n=3)	45.2 (2.2)	10.8 (1.6)*	43.1 (2.8)	11.3 (1.8)*	44.0 (3.7)
SA005 (n=3)	42.8 (7.3)	11.4 (1.7)*	38.3 (2.6)	8.2 (1.8)*	38.4 (5.7)
SA154 (n=3)	39.7 (5.6)	14.9 (8.7)*	37.7 (5.5)	13.5 (7.7)*	40.0 (2.6)
SA162 (n=3)	49.1 (2.1)	8.5 (1.4)*	30.1 (0.8)	6.0 (0.6)*	31.2 (4.0)
SA222 (n=5)	36.8 (2.7)	13.2 (0.7)*	37.9 (4.7)	14.0 (2.4)*	34.4 (3.9)
SA250 (n=3)	36.0 (6.8)	15.8 (6.7)*	31.3 (5.7)	13.0 (5.8)*	33.4 (5.6)
CM028 (n=5)	43.6 (7.3)	9.4 (5.2)*	39.4 (6.5)	9.6 (5.9)*	40.4 (5.6)
CM033 (n=3)	37.5 (2.4)	10.8 (3.5)*	38.9 (4.0)	10.0 (3.7)*	36.5 (4.4)

P. falciparum isolates SA005, SA154, SA162, SA222, SA250, JASC8-19, CM028, and CM033 were collected from children with malaria in western Kenya, while 3D7 is laboratory-adapted strain. Parasites were cultivated on RPMI containing 0.2% NaHCO₃, 0.1 mM hypoxanthine and 10% normal serum (type O+), maintained at 37 °C and a gas mixture of 90% N₂, 5% O₂ and 5% CO₂. Invasion assays were set up in duplicates in 96-well plates with 100 μ L/well of culture media. Uninfected untreated erythrocytes or neuraminidase-treated erythrocytes at 2% hematocrit were inoculated with purified schizonts to obtain 1–2% parasitemia. CR1-mediated invasion was inhibited with either 50 μ g/mL of sCR1 or 8 μ g/mL of polyclonal chicken IgY raised against sCR1 (Gallus Immunotech Inc., Fergus, Canada). Fetuin and α -2-macroglobulin (α -2-M) were used as control proteins, and chicken IgY as control antibody. After overnight incubation, erythrocytes were stained with Hoechst 33342 and invasion rates were calculated as the percentage of ring-infected erythrocytes as determined by flow cytometry using a LSR-II system (Becton-Dickinson, San Diego, CA). "n" denotes the number of experiments. Data are presented as means (SD) of three to five separate experiments for each parasite strain.

* Indicates that invasion inhibition by anti-CR1 or sCR1 was statistically significant compared to the effects of IgY or α -2-M and fetuin, respectively ($P < 0.05$ vs respective control proteins, paired Student's *t*-test).

Reed Army Institute of Research. The parasites were cultured for 1–2 weeks to adapt and synchronize before invasion assays were performed. Schizonts were purified using Percoll gradient centrifugation and used to inoculate uninfected erythrocytes at 1–2%. Each experiment was set up in duplicate wells, and invasion rates were averaged between the 2 wells. Three to five separate invasion experiments were performed at 2-day intervals for each isolate. Treatment of erythrocytes with the anti-CR1 polyclonal antibody decreased invasion by 10–18% in all the parasites tested (Table 1). The inhibitory effects elicited by anti-CR1 were statistically significant compared to the changes induced by control IgY antibodies in four out of eight isolates tested ($P < 0.05$, Table 1). In addition, invasion of untreated erythrocytes by all parasite isolates tested was inhibited by as much as 20–35% in the presence of sCR1. Compared to the effects of control proteins α -2-macroglobulin (α -2-M) or fetuin, inhibition of invasion by sCR1 was statistically significant in seven out of eight parasite strains examined ($P < 0.05$, Table 1). In contrast, invasion of untreated erythrocytes by laboratory strains such as 3D7 were not significantly affected by the presence of CR1 inhibitors (Table 1 and [10]), demonstrating the important contribution that CR1 makes to invasion of the intact red cells by field parasites.

All parasite isolates were capable of invading red cells in a SA-independent manner, retaining 36–49% of their normal invasion levels after erythrocytes were treated with neuraminidase (Table 1). For comparison, 3D7 on the average retained 62% of its invasion after treatment of erythrocytes with neuraminidase (Table 1). Anti-CR1 significantly inhibited invasion of neuraminidase-treated erythrocytes in all parasites ($P < 0.01$ compared to IgY for all isolates; Table 1). These effects of anti-CR1 represented a 60–85% inhibition of SA-independent invasion in the eight field parasites, suggesting that CR1 plays an important role in SA-independent erythrocyte invasion. Furthermore, sCR1 similarly decreased invasion of neuraminidase-treated erythrocytes in the clinical parasites by 65–90% ($P < 0.01$ compared to control

for all isolates). The relatively lower dependence of these parasites on CR1 for invasion of untreated erythrocytes compared to neuraminidase-treated erythrocytes is consistent with the existing notion that glycoporphins are the primary or preferred receptors for *P. falciparum*. Consistent with our observations in laboratory strains [10], these results indicate that CR1 is the previously unknown SA-independent receptor used by a majority of wild *P. falciparum* isolates.

To assess the extent of genetic diversity among the parasite isolates that use CR1 as an invasion receptor, a sequence analysis of the highly polymorphic C1 cluster of *P. falciparum* AMA-1 domain 1 was performed. AMA-1 plays a key role in erythrocyte invasion [17], and amino acid substitutions within the C1 cluster have been shown to confer antigenic escape from invasion inhibitory antibodies [18]. As controls, two clones of JASC8-19 (JASC8-8 and JASC8-10), as well as the laboratory strain 3D7 (GenBank accession number U65407.1) were also analyzed. These analyses revealed that seven isolates, JASC8-19, SA005, SA154, SA162, SA222, SA250, and CM028, were genetically distinct with >25% differences in amino acid sequences between some of them (Fig. 1). The eighth parasite, CM033, had a sequence that was identical to SA154 at the same locus, suggesting that these could be the same parasite. Furthermore, multiple AMA1 sequences were detected in SA162 and CM028, indicating that these isolates were mixtures of at least two different parasites. Within the 30-amino acids spanning the C1 cluster, the sequences of the seven distinct isolates differed from 3D7 by three to nine amino acid residues (Table 2). Therefore, the use of CR1 as a receptor for SA-independent invasion of erythrocytes was conserved across a genetically diverse group of parasites. These data argue for a broad reliance on CR1 as the major SA-independent receptor in widely diverse field strains.

Our previous investigations demonstrated that CR1 is a major receptor used by many laboratory strains of *P. falciparum* for SA-independent invasion of erythrocytes [10]. Those findings marked an important step towards the understanding of erythrocyte inva-

U.S. Government has the right to retain a nonexclusive, royalty-free license in and to any copyright covering this paper.

Acknowledgements

We are grateful to Chris Ockenhouse for providing material and logistical support for parts of the study. The authors are also grateful for technical support from Juliana Harris of the Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland, 20814, USA, and Shannon Mcgrath of the Division of Malaria Vaccine Development, WRAIR.

References

- [1] WHO. World malaria report 2005. Geneva: World Health Organization/United Nations Children's Fund; 2005. http://www.rollbackmalaria.org/wmr2005/pdf/WMReport_Ir.pdf.
- [2] Deas JE, Lee LT. Competitive inhibition by soluble erythrocyte glycoproteins of penetration by *Plasmodium falciparum*. *Am J Trop Med Hyg* 1981;30:7–1164.
- [3] Maier AG, Duraisingh MT, Reeder JC, et al. *Plasmodium falciparum* erythrocyte invasion through glycophorin C and selection for Gerbich negativity in human populations. *Nat Med* 2003;9:87–92.
- [4] Mitchell GH, Hadley TJ, McGinniss MH, Klotz FW, Miller LH. Invasion of erythrocytes by *Plasmodium falciparum* malaria parasites: evidence for receptor heterogeneity and two receptors. *Blood* 1986;67:21–1519.
- [5] Deans AM, Nery S, Conway DJ, Kai O, Marsh K, Rowe JA. Invasion pathways and malaria severity in Kenyan *Plasmodium falciparum* clinical isolates. *Infect Immun* 2007;75:20–3014.
- [6] Dolan SA, Miller LH, Wellems TE. Evidence for a switching mechanism in the invasion of erythrocytes by *Plasmodium falciparum*. *J Clin Invest* 1990;86:24–618.
- [7] Hadley TJ, Klotz FW, Pasvol G, et al. *Falciparum* malaria parasites invade erythrocytes that lack glycophorin A and B (MkMk) strain differences indicate receptor heterogeneity and two pathways for invasion. *J Clin Invest* 1987;80:3–1190.
- [8] Okoyeh JN, Pillai CR, Chitnis CE. *Plasmodium falciparum* field isolates commonly use erythrocyte invasion pathways that are independent of sialic acid residues of glycophorin A. *Infect Immun* 1999;67:91–5784.
- [9] Baum J, Pinder M, Conway DJ. Erythrocyte invasion phenotypes of *Plasmodium falciparum* in The Gambia. *Infect Immun* 2003;71:163–1856.
- [10] Spadafora C, Awandare GA, Kopydlowski KM, et al. Complement receptor 1 is a sialic acid-independent erythrocyte receptor of *Plasmodium falciparum*. *PLoS Pathog* 2010;6:e1000968.
- [11] Tham WH, Wilson DW, Lopaticki S, et al. Complement receptor 1 is the host erythrocyte receptor for *Plasmodium falciparum* PfRh4 invasion ligand. *Proc Natl Acad Sci U S A* 2010;107:17327–32.
- [12] Stoute JA, Odindo AO, Owuor BO, Mibeik EK, Opollo MO, Waitumbi JN. Loss of red blood cell-complement regulatory proteins and increased levels of circulating immune complexes are associated with severe malarial anemia. *J Infect Dis* 2003;187:5–522.
- [13] Waitumbi JN, Opollo MO, Muga RO, Misore AO, Stoute JA. Red cell surface changes and erythrophagocytosis in children with severe *Plasmodium falciparum* anemia. *Blood* 2000;95:6–1481.
- [14] Thathy V, Moulds JM, Guyah B, Otieno W, Stoute JA. Complement receptor 1 polymorphisms associated with resistance to severe malaria in Kenya. *Malar J* 2005;4:54.
- [15] Teeranaipong P, Ohashi J, Patarapotikul J, et al. A functional single-nucleotide polymorphism in the CR1 promoter region contributes to protection against cerebral malaria. *J Infect Dis* 2008;198:91–1880.
- [16] Khera R, Das N. Complement receptor 1: disease associations and therapeutic implications. *Mol Immunol* 2009;46:72–61.
- [17] Triglia T, Healer J, Caruana SR, et al. Apical membrane antigen 1 plays a central role in erythrocyte invasion by *Plasmodium* species. *Mol Microbiol* 2000;38:18–706.
- [18] Dutta S, Lee SY, Batchelor AH, Lanar DE. Structural basis of antigenic escape of a malaria vaccine candidate. *Proc Natl Acad Sci U S A* 2007;104:93–12488.
- [19] Persson KE, McCallum FJ, Reiling L, et al. Variation in use of erythrocyte invasion pathways by *Plasmodium falciparum* mediates evasion of human inhibitory antibodies. *J Clin Invest* 2008;118:51–342.
- [20] Marshall VM, Zhang L, Anders RF, Coppel RL. Diversity of the vaccine candidate AMA-1 of *Plasmodium falciparum*. *Mol Biochem Parasitol* 1996;77:13–09.